News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EnWave Corporation (ENW.V) Announces quantaREV(TM), a New High-Capacity Dehydration Technology Platform, and Files Patent


1/4/2011 9:11:46 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - January 04, 2011) - EnWave Corporation (TSX VENTURE: ENW)(FRANKFURT: E4U) ("EnWave" or "the Company") today announced the launch of quantaREV™, the Company's fifth Radiant Energy Vacuum ("REV") dehydration technology platform, designed to meet the requirements of food and chemical production companies for high-volume continuous, low-temperature dehydration of solids, liquids, granular or encapsulated products. quantaREV™ introduces a continuous belt design within a controlled vacuum-microwave environment, allowing the potential for dehydration of up to several tonnes of material per hour, a significant innovation in EnWave's REV dehydration technology.

"While all of our REV technologies are designed to increase the speed of dehydration, improve the quality of the final product and reduce costs, we believe quantaREV™ will provide a compelling solution for those industrial users requiring high through-put drying of heat-sensitive materials such as nutrient-rich foods or foods where colour, flavour or texture could be improved," said Dr. Tim Durance, EnWave's Chairman and Co-CEO. "If, as we believe, we can achieve tonnes per hour in REV drying capacity with quantaREV™, it will open many new highly attractive markets for our technology. It is also of interest to several companies with which we are currently working. High volume REV technology may compete successfully with other large-capacity drying technologies, or be used as a new technology to deliver new or improved food and chemical products to the market."

"Our growing list of multi-national collaborations is an indication of how exceptionally well positioned we are to bring our proprietary industrial dehydration technology to market," said John McNicol, EnWave's President and Co-CEO. "We know that there is a global need for high-volume dehydration and, with the addition of quantaREV™, we now have platforms that may be used to compete with all three major forms of commercial dehydration: freeze drying, spray drying and air drying."

EnWave recently completed tests on a prototype of this technology in its engineering facilities in Delta, B.C., and has filed a patent to protect this innovation. The Company is now constructing a larger, pilot-scale version of quantaREV™ for installation in its pilot plant, and expects the unit to be available for paid customer trials in the first quarter of 2011.

EnWave's new quantaREV™ dehydration technology uses a continuous belt design in a vacuum-microwave environment in order to accommodate a wide range of input materials. quantaREV™will complement EnWave's current suite of dehydration technologies which include nutraREV™, a commercial technology used for drying discrete food pieces in a tumbling vacuum-microwave environment, and powderREV™, an accelerated freeze drying process currently being tested as a means for bulk drying of biomaterials such as probiotics and enzymes. The Company also has two other prototype dehydration technologies, bioREV™ and freezeREV™, both of which are designed to dry biomaterials in vials such as vaccines and other biopharmaceuticals, scientific reagents, and medical diagnostic materials.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is commercializing a new method for dehydrating food and biological materials using Radiant Energy Vacuum ("REV") technology under its nutraREV™, powderREV™, quantaREV™, bioREV™ and freezeREV™ brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at: www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

For further information:

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Contacts:
EnWave Corporation
Mr. John McNicol
President & Co-CEO
(604) 601-8524
john.mcnicol@enwave.net

EnWave Corporation
Jennifer Thompson
V.P. Corporate Development & Investor Relations
(604) 603-6549
jthompson@enwave.net
www.enwave.net


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES